# **A Metabolic Biomarker Panel for Congenital Heart Disease Assessment**

# 2 with Newborn Dried Blood Spots

- <sup>3</sup> Scott R. Ceresnac<sup>1\*</sup>, Yaqi Zhang<sup>2,3\*</sup>, Kuo Jung Su<sup>4</sup>, Qiming Tang<sup>4</sup>, Bo Jin<sup>4</sup>,
- <sup>4</sup> James Schilling<sup>4</sup>, C. James Chou<sup>3</sup>, Zhi Han<sup>3</sup>, Brendan J. Floyd<sup>5</sup>, John C.
- 5 Whitin<sup>5</sup>, Karl G Sylvester<sup>3</sup>, Henry Chubb<sup>1</sup>, Ruben Y. Luo<sup>6</sup>, Lu Tian<sup>7</sup>, Harvey J.
- 6 Cohen<sup>5</sup>, Doff B. McElhinney<sup>1</sup>, Xuefeng B. Ling<sup>3\*</sup>
- 7
- <sup>8</sup> <sup>1</sup>Department of Cardiothoracic Surgery, Stanford University, Stanford, CA,
- 9 United States
- <sup>10</sup> <sup>2</sup>School of Electrical Power Engineering, South China University of
- 11 Technology, Guangzhou, China
- <sup>12</sup> <sup>3</sup>Department of Surgery, Stanford University, Stanford, CA, United States
- <sup>13</sup> <sup>4</sup>mProbe Inc, Palo Alto, CA, United States
- <sup>14</sup> <sup>5</sup>Department of Pediatrics, Stanford University, Stanford, CA, United States
- <sup>15</sup> <sup>6</sup>Department of Pathology, Stanford University, Stanford, CA, United States
- <sup>16</sup> <sup>7</sup>Department of Data Science, Stanford University, Stanford, CA, United States

17

- 18
- 19 \*Corresponding Author:
- 20 <u>ceresnak@stanford.edu</u>, <u>vaqizhang@gpnu.edu.cn</u>, <u>bxling@stanford.edu</u>

#### 21 Abstract

22 Background: Congenital heart disease (CHD) represents a significant contributor to both morbidity and mortality in neonates and children. The 23 prompt recognition of CHD can facilitate timely and appropriate intervention, 24 reducing the probability of complications and enhancing the prognosis for 25 impacted newborns. However, unlike other rare conditions routinely identified 26 through federal and state newborn screening (NBS) programs, there's 27 28 currently no analogous dried blood spot (DBS) screening for CHD immediately 29 after birth.

30 **Objective:** This study was set to identify reliable metabolite biomarkers with 31 clinical relevance, with the aim to assess feasibility of screening and subtype 32 classification of CHD utilizing the DBS newborn screening method.

33 Methods: We assembled a cohort of DBS datasets from the California 34 Department of Public Health (CDPH) Biobank, encompassing both normal 35 controls and three pre-defined CHD categories (tetralogy of Fallot, inherited arrhythmia syndrome, neonatal cardiomyopathy). A robust, DBS-oriented 36 metabolomic method, employing both global and targeted strategies based on 37 liquid chromatography with tandem mass spectrometry (LC-MS/MS), was 38 developed. To verify the reliability of this metabolic profiling, we conducted a 39 40 correlation analysis comparing the absolute quantitated metabolite 41 concentration in DBS against the CDPH NBS records. Additionally, for hydrophilic and hydrophobic metabolites, we executed significant pathway and 42 metabolite analyses respectively. Finally, logistic and LightGBM models were 43 established to aid in CHD discrimination and classification. 44

45 Results: Our metabolomic workflow demonstrated consistent and reliable 46 quantification of metabolites in DBS samples stored at the California 47 Department of Public Health (CDPH) for up to 15 years. Through this process, 48 we discerned dysregulated metabolic pathways in CHD patients, including deviations in lipid and energy metabolism, as well as oxidative stress pathways. 49 Furthermore, we identified three metabolites as potential biomarkers for CHD 50 51 assessment, and an additional twelve metabolites as potential markers for classifying different CHD subtypes within DBS samples. 52

Conclusions: This study represents the first attempt to validate metabolite profiling results using long-term storage DBS samples procured from the high-quality conditions of the CDPH biobank. The results unveil distinct metabolic discrepancies between various CHD subtypes and healthy controls. Furthermore, our findings highlight the potential clinical applications of our DBS-based methods for CHD screening and subtype classification.

59

# 60 Introduction

61 Congenital heart disease (CHD) ranks as the most prevalent form of 62 congenital anomalies<sup>1,2</sup>, making it a significant contributor to morbidity and 63 mortality <sup>3,4</sup>, among neonates and children. With its birth prevalence on an 64 upward trend, CHD has evolved into a major global health concern.

The importance of early diagnosis is paramount for the effective CHD 65 66 intervention and treatment. Prenatal diagnosis and early detection advancements have contributed to a gradual decline in the mortality rate 67 associated with CHD in children<sup>5</sup>. Various screening approaches for the 68 detection of cyanotic congenital heart disease have been implemented and 69 examined, including neonatal pulse oximetry screening<sup>6</sup> and universal ECG 70 screening<sup>7,8</sup>. However, these methodologies exhibit less than 75% sensitivity 71 72 in detecting critical CHD, presenting limitations in the detection of an array of 73 congenital malformations, cardiomyopathic disorders, and inherited arrhythmia 74 syndromes. These conditions contribute significantly to neonatal mortality and sudden death in children and adolescents<sup>9</sup>. Currently, there is no 75 comprehensive, cost-effective screening method available at birth that can 76 reliably and consistently detect the diverse range of CHD conditions that could 77 potentially harm infants and children later in life. 78

Over the past decade, the application of cardiac-specific biomarkers, proteomic and metabolite analysis, mRNA, and small molecule screens has seen a significant increase<sup>10-12</sup>. The discovery of biomarkers associated with cardiac dysfunction, myocardial cell damage, and heart-specific tissue damage heralds a shift in our approach to screening, assessing, and treating

cardiac diseases. It has been shown that structural abnormalities, such as the 84 metabolism of acylcarnitines<sup>13</sup>, can create detectable metabolomic 85 86 disturbances. Physiological alterations linked to cyanosis in cyanotic 87 congenital heart disease, hemodynamic changes tied to volume and pressure loading in non-cyanotic lesions, tissue injury due to perfusion abnormalities in 88 89 cardiomyopathic states, and cellular changes related to potassium, calcium, 90 and sodium exchange defects in channelopathies, could all lead to distinguishable differences in the metabolomic profiles of neonates and 91 children with cardiac disease<sup>14-18</sup>. 92

Routine neonatal screening serves as a tool to identify diseases that could potentially impact a child's long-term health or survival. Each year, millions of infants in the United States undergo newborn screening (NBS), where substances in dried blood spots (DBS) are measured to check for certain genetic, endocrine, and metabolic disorders<sup>19</sup>. Early detection, diagnosis, and intervention can avert death or disability, enabling children to reach their full potential. Despite this, no DBS newborn screening exists for CHD at birth.

Our core hypothesis proposes that deep phenotyping of DBS metabolites at birth through liquid chromatography-mass spectrometry (LC-MS) could model and assess cardiac and other organ anomalies with high precision. This hypothesis was previously tested with our DBS analyses assessing other neonatal diseases<sup>20</sup>.

In this study, we developed an LC-MS based metabolic screening method to
 construct a baseline for neonate DBS metabolites and identify a DBS
 biomarker panel as a molecular surrogate to assess congenital cardiac

108	abnormalities. Our findings attest to the robustness of our DBS-based LC-MS
109	workflow, supporting the idea that assessing DBS metabolomic biomarkers
110	may present a cost-effective and sturdy approach to evaluating the risk of CHD
111	at birth. Further understanding the functional significance of these CHD
112	biomarkers could provide fresh insights into the pathophysiology of CHD.

# 113 Methods

#### 114 **Ethics statement**

- 115 This DBS NBS method development study involving human participants was
- reviewed and approved by ethics committees at Stanford University.

#### 117 Study design

The workflow for this study, as depicted in Fig. 1, was based on the collected 118 dried blood spot (DBS) samples. Both global hydrophilic/hydrophobic and 119 targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) 120 121 metabolomic assays were conducted, adhering to the NBS DBS processing method. To verify the reliability of the metabolic profiling from samples that had 122 123 been stored for years, a correlation analysis was carried out comparing the 124 absolutely-quantified metabolite concentration with the California Department 125 of Public Health (CDPH) gold standard. We identified significant metabolic pathways and features related to CHD and its subtypes. Finally, models for 126 127 CHD diagnosis and subtyping were established to validate the effectiveness of 128 the CHD-associated metabolic biomarker panel within the DBS samples.

129 Cohorts

130	We randomly assembled a retrospective cohort of DBS profiling datasets from
131	the CDPH Biobank. These DBS samples had been stored for up to 15 years
132	since the time of newborn testing analysis, consented to be preserved at -20°C
133	in the CDPH Biobank. In total, we included 20 clinical DBS samples, consisting
134	of 5 healthy controls (HC) and 15 cases of CHD spanning different categories.
135	The 15 CHD cases included 4 instances of Tetralogy of Fallot (TOF), 5 cases
136	of inherited arrhythmia syndromes (IAS), and 6 instances of cardiomyopathies
137	(CMP).

138 Sample preparation

The DBS samples were retrieved from -20°C freezers and thawed on ice. Each
DBS sample was cut into 3mm diameter sections, and two of these sections
were transferred into the same Eppendorf tube.

# 142 Global hydrophilic and targeted metabolomics

We followed our previously developed standard operational protocols<sup>21</sup> of global hydrophilic and targeted metabolomics for the workflow in this study, including sample preprocessing, mass spectrometry signal acquisition, quality control, data pre-processing, and metabolite biomarker structural identification.

For global hydrophilic metabolomics, a mixture of 250  $\mu$ L extraction buffer (pre-chilled to -20 °C) consisting of methanol, acetonitrile and ddH2O (5:3:2 v/v) was added to each tube containing DBS punches. Samples were vortexed and centrifuged at 10,000 g for 10 min at 4°C. Supernatant (180  $\mu$ L) from each sample was transferred into a clean Eppendorf tube. 100  $\mu$ L of each sample

extract was transfer into an auto-sampler vial for UHPLC-MS (Ultra-High
 Performance Liquid Chromatography) analysis.

154 For targeted metabolomics, a mixture of 200  $\mu$ L methanol / acetonitrile (1:1, v/v) was added into the tube containing DBS punches. Samples were vortexed 155 vigorously and centrifuged at 10,000 g for 10 min at 4°C. The supernatant of 156 each sample was transferred into a new tube and dried under nitrogen stream. 157 10 µL of Internal Standard Solution, 90 µL of Extraction Buffer, and 200 µL 158 159 hexane were added into the reconstituted tube for extraction. The sample was 160 vortexed vigorously for 1 min and centrifuged at 12,000 g for 5 min. 180 µL of 161 upper layer was transferred into another 1.5-mL centrifugal tube and dried under nitrogen stream again. The residue was reconstituted with 100 µL of 162 163 Derivatization Buffer. The reconstituted sample was incubated at 95°C for 15 min. After derivatization, 100 µL of each reconstituted sample was transferred 164 into an auto-sampler vial for the analysis of fatty acids. 80 µL of lower layer 165 166 was transferred into an auto-sampler vial for the analysis of amino acids and 167 acylcarnitines.

#### 168 **Global hydrophobic metabolomics**

For global hydrophobic metabolomics, a mixture of 400  $\mu$ L of chloroform / methanol (1:1, v/v) and 200  $\mu$ L of water with lithium chloride were added to each tube containing DBS punches. Afterwards, the sample was vortexed rigorously for 30 sec and centrifuged at 12,000 g for 5 min. The bottom layer of each sample was transfered into another tube. The top layer was re-extracted with 400  $\mu$ L of chloroform and vortexed for 30 sec and centrifuged at 12,000 g for 5 min. The bottom layer was removed and combined with extract from

previous trial. The combined extract was dried under nitrogen and reconstituted with 100  $\mu$ L of methanol: chloroform (1:1, v/v). Thereafter, the DBS extract was transferred into auto-sampler vial with micro-insert for LC/MS analysis.

For global hydrophobic metabolomics, 5 µL of DBS extract was injected via a 180 181 Vanguish UHPLC system. The mobile phase was methanol with 10 mM 182 ammonium acetate at a flow rate of 0.1 mL/min for a total run time of 3 minutes. 183 The conditions of ionization source were set at 3.4 kV for spray voltage, 15 for 184 sheath gas, 5 for aux gas, 325°C for capillary temperature, 55 for S-lens, and 185 250°C for vaporizer temperature. The MS spectra were acquired with 2 scans using an AGC target of 1e6 and a resolution of 120,000 (FWHM at 200 m/z) 186 187 from 200 to 1200 m/z. The column oven was maintained at 25°C throughout the analysis. 188

Metabolic pathway enrichment analysis with global hydrophilic and
 hydrophobic metabolomics

To carry out pathway enrichment analysis on both hydrophilic and hydrophobic mass spectrometric profiling results, a univariate analysis was utilized to compute the fold change and p-value (using Student's t-test) for each component across the three different CHD subtypes. Following the correction for false discovery, components that showed significant changes (adjusted p-value < 0.05) were chosen for subsequent analysis.

All significantly altered hydrophilic metabolites were categorized into KEGG
 pathways<sup>22</sup> for further examination, while significantly changed hydrophobic

<sup>199</sup> metabolites were grouped into the Lipid Map database<sup>23</sup>. Enriched pathways

of significance were identified with a Fisher's exact test p-value of < 0.05.

201 Statistic learning for multi-class classification

Orthogonal partial least squares discriminant analysis (OPLS-DA) was performed using global hydrophilic and hydrophobic metabolic profiling results. Unsupervising clustering results were used to visualize the two-dimensional clustering patterns of HC, TOF, IAS and CMP DBS samples. With OPLS-DA results, the performance of the discrimination between two of these DBS sample categories was assessed using a receiver operating characteristic curve (ROC) and the area under the curve (AUC).

To distinguish between CHD patients and healthy controls, a logistic model<sup>24</sup> 209 210 was constructed based on targeted metabolomic profiling results. For CHD 211 subtyping, the importance of identified targeted metabolites was determined using a gradient boosting machine provided by the LightGBM library<sup>25</sup>. 212 213 Analysis was implemented with default parameters, and the metric used for 214 early stopping was set to the error rate for multi-class classification<sup>26</sup>. 215 Metabolites were then ranked based on their normalized importance scores. 216 Metabolites with cumulative importance greater than 80% were selected as 217 biomarkers.

The significantly relevant biomarker metabolites associated with CHD diagnosis and subtyping were then proposed and discussed.

220 **Results** 

#### 221 Demographics and Clinical Characteristics

222	Table 1 summarizes the cohort demographics and clinical characteristics. This
223	includes a cohort of 20 neonates, comprising of 5 controls and 15 CHD
224	patients. Of these 20 neonates, 11 were boys (55%) and 9 were girls (45%).
225	The 15 CHD patients comprised 4 diagnosed with CHD-Tetralogy of Fallot
226	(TOF), 5 with CHD-inherited arrhythmia syndromes (IAS (2 Brugada, 3 Long
227	QT syndrome)), and 6 with CHD-cardiomyopathies (CMP (3 dilated, 3
228	hypergtrophic cardiomyopathy)). No statistically significant differences were
229	observed in the distribution of gender and race across all groups.

The DBS samples had been stored in the CDPH biobank at -20 °C for up to 15 years, as shown in Fig. 2. We reanalyzed the concentrations of 28 metabolites, which are common to the CDPH DBS NBS records (Table 1) and include amino acids, free carnitines, and acylcarnitines. Fig. 3 shows that 24 out of the 28 metabolites exhibit a strong correlation, affirming both the robustness of our metabolomic profiling workflow and the reliability of these DBS samples even after many years of storage.

237 Exploration of the unique metabolic patterns among different CHD subtypes

Two distinct high-throughput global mass spectrometric workflows were conducted, focusing on hydrophilic and hydrophobic metabolites separately. After data preprocessing, a total of 1829 compounds were identified in the global hydrophilic metabolomic profiling, and 1383 compounds were identified in the global hydrophobic metabolomics. Multivariate analysis, specifically sparse partial least squares discriminant analysis (OPLS-DA), was then performed on the global hydrophilic and hydrophobic metabolomics to investigate different CHD subtypes, including TOF, IAS, and CMP. The results, presented in **Fig. 4** and **Table 2**, revealed distinct clustering patterns for samples from various CHD subtypes in both the global hydrophilic and hydrophobic metabolic profiling.

Interestingly (**Fig. 4** and **Table 2**), CHD-IAS could not be reliably distinguished from other groups (ROC AUC, 0.607; P value, 0.458) based on the global hydrophilic metabolomics, while CHD-CMP also showed poor distinction from other groups (ROC AUC, 0.533; P value, 0.827) based on the global hydrophobic metabolomics. These findings suggest that each CHD subtype may indeed exhibit unique metabolic differences compared to both the healthy control and other CHD subtype groups.

# Pathway analysis with global hydrophilic and hydrophobic metabolomics

258 To identify specific metabolic differences in CHD subtypes, pathway 259 enrichment analysis was performed on the significant changes observed in global metabolism (adjusted P value < 0.05) (Fig. 5). For hydrophilic 260 261 metabolites, the KEGG pathway database was utilized, while the Lipids Map 262 database was used for hydrophobic metabolites. The results depicted in Fig. 5 263 show that the Arachidonic acid metabolism and Monoradylglycerols pathways are consistently and significantly enriched in all three CHD subtypes. 264 Additionally, the Linoleic acid metabolism, serotonergic synapse, and 265 sphingoid bases pathways are significantly enriched solely in the IAS and TOF 266

267 subtypes of CHD. Moreover, Quinones and hydroquinones were found to be 268 significantly enriched only in CHD-CMP, while Arginine and ornithine 269 metabolism showed significant enrichment exclusively in CHD-IAS. These 270 findings suggest the presence of diverse metabolic pathway changes among 271 the different CHD subtypes, emphasizing the importance of considering both 272 hydrophilic and hydrophobic metabolites when constructing a CHD diagnosis 273 panel. Such a comprehensive approach will enable a more accurate and informative characterization of the metabolic profiles associated with different 274 275 CHD subtypes.

276 Identification of a metabolic signature for CHD

Using our targeted metabolomics methods, we conducted quantitative measurements of 836 targeted metabolites and lipids in DBS samples collected from both CHD patients and healthy controls. Upon comparing CHD patients with healthy controls, we identified 3 biomarker metabolites (p < 0.05) through univariate analysis, namely PC(d16:1-22:3), C14:1-Carnitine, and C12-Carnitine (**Fig. 6A** and **Fig. 6B**).

To further explore the diagnostic potential of these biomarkers, we constructed a logistic model based on their concentrations. This logistic model exhibited high accuracy in distinguishing between CHD patients and healthy controls, achieving an area under the curve (AUC) of 0.982 (95% CI: 0.92-1.00) (**Fig. 6C**). The sensitivity and specificity of this logistic model were 92.8% and 75.0%, respectively. 289 Regarding the metabolic signature for CHD subtyping, we employed the 290 LightGBM model to calculate the importance of each metabolite in the 291 multiclass classification of the three types of CHD. This analysis revealed 12 292 crucial metabolites required to achieve 80% cumulative importance (Fig. 6D). These significant metabolites 293 include Alanine, C10-Carnitine, 294 TG(16:0-16:0-20:2), TG(16:1-18:2-18:3), PE(a20:0-20:2), C10:1-Carnitine, 295 Octacosanoic acid(28:0), C14:10H-Carnitine, C8:1-Carnitine, Asparagine, C0-Carnitine, and d18:0 CE. 296

Following that, OPLS-DA analysis was carried out using the aforementioned 12 metabolites (**Fig. 6E**). The results, as shown in **Fig. 7**, revealed an AUC of 0.963 (P value = 0.03) for distinguishing CMP vs Other, an AUC of 0.98 (P value = 0.03) for distinguishing IAS vs Other, and an AUC of 0.84 (P value = 0.05) for distinguishing TOF vs Other. These findings indicate promising discriminatory capabilities of the selected metabolites in identifying different CHD subtypes when compared to the other groups.

304 Discussion

#### 305 Summary of main findings

To explore the identification of CHD metabolic biomarkers using dried blood DBS samples, we began by verifying the reliability of the metabolic profiling from these samples, even after years of storage. This was achieved through correlation analysis of the absolute quantitated metabolite concentrations from this study and the CDPH database records. Subsequently, utilizing global and

311	targeted LC-MS/MS metabolomic profiling methods, we further analyzed the
312	significant metabolic pathways associated with CHD and its subtypes.
313	In the process, we established models for CHD diagnosis and subtyping to
314	validate the effectiveness of the CHD-associated metabolic patterns. Our
315	findings revealed distinct metabolic differences in significant pathways and
316	unique metabolic patterns related to both CHD and its subtypes. Furthermore,
317	using targeted metabolomics, we identified 3 biomarker metabolites for CHD
318	diagnosis and 12 biomarker metabolites for CHD subtyping. These results
319	support the hypothesis that serial LC-MS profiling of DBS metabolites from
320	newborns may hold potential in accurately assessing CHD and offer a
321	non-invasive and cost-effective method for CHD detection.
322	Overall, this study sheds light on the potential of utilizing metabolic profiling
323	from DBS samples as a precise and efficient means of CHD diagnosis, paving
324	the way for improved early detection and management of this condition.
325	The stability of amino acid and acyl carnitines in DBS
326	In this study, we utilized CHD DBS samples obtained from the CDPH Biobank,
327	an invaluable resource for research due to its extensive collection of biological
328	specimens suitable for various types of investigations, including
329	epidemiological, genetic, and biomarker research. However, concerns
330	

<sup>331</sup> periods have been raised, limiting retrospective analyses using stored DBS.

To address this concern and ensure the accuracy and reliability of metabolomic studies, we focused on assessing the stability of acylcarnitines and amino acids in DBS stored in freezers after newborn screening. Our research aimed to shed light on the long-term stability of these metabolites in stored specimens.

The encouraging findings of our study revealed excellent stability for both amino acids and acyl carnitines, even after up to 15 years of storage. This discovery provides reassurance that dried blood specimens stored in the CDPH biobank freezers can be reliably used for metabolomic studies, even following prolonged storage. This insight enhances the confidence in utilizing the biobank's stored samples for future investigations, contributing to the advancement of CHD and other related research areas.

#### 344 **CHD** biomarker biological implications

345 Informative alterations in plasma metabolite concentrations related to specific 346 metabolic pathways have been found to be associated with the CHD pathogenesis and pathophysiology<sup>27</sup>. A notable example is the significant 347 involvement of fatty acid metabolism in hypertrophied newborn hearts, where it 348 plays a crucial role in energy generation<sup>28</sup>. In our investigation, we discovered 349 a significant association between the arachidonic acid (AA) metabolism 350 351 pathway and the pathophysiology of various CHD subtypes, including TOF, 352 IAS, and CMP (Fig. 5A). The AA metabolism pathway is intricate, involving the 353 metabolism of arachidonic acid, an omega-6 fatty acid, by enzymes like cyclooxygenases (COX), lipoxygenases (LOX), and cytochrome P450 (CYP) 354 355 enzymes. This pathway gives rise to diverse bioactive lipid mediators, such as

prostaglandins, thromboxanes, leukotrienes, and epoxyeicosatrienoic acids (EETs), which play essential roles in various physiological and pathological processes<sup>29</sup>.

359 Previous studies have demonstrated that dysregulation of the AA metabolism pathway is linked to the development and progression of CHD. For instance, in 360 TOF, a common CHD type, there is evidence of increased oxidative stress and 361 inflammation<sup>30,31</sup>, leading to potential dysregulation of the AA metabolism 362 363 pathway. Such dysregulation could result in the overproduction of 364 vasoconstrictive and pro-inflammatory mediators, such as thromboxane A2 365 and leukotriene B4, contributing to pulmonary hypertension and exacerbating right ventricular dysfunction<sup>32,33</sup>. Similarly, in inherited arrhythmia syndromes 366 like long QT syndrome and Brugada syndrome, genetic mutations in ion 367 channel genes can alter AA metabolism and lead to the production of EETs. 368 These EETs can modulate ion channel activity, affecting cardiac repolarization 369 and leading to arrhythmias and sudden cardiac death<sup>34-36</sup>. In cardiomyopathies 370 371 such as hypertrophic cardiomyopathy and dilated cardiomyopathy, elevated 372 inflammation and fibrosis have been observed, potentially contributing to the dysregulation of the AA metabolism pathway<sup>37,38</sup>. Consequently, the 373 374 overproduction of pro-inflammatory and pro-fibrotic mediators, such as 375 prostaglandin E2 and leukotriene B4, may play a role in cardiac remodeling 376 and dysfunction. Overall, our findings highlight the relevance of the AA 377 metabolism pathway in CHD pathogenesis and shed light on its potential as a 378 target for further research and therapeutic interventions.

379 Pathway enrichment analysis conducted on the global metabolic profiling 380 revealed a particularly significant change in the linoleic acid (LA) metabolic 381 pathway in TOF and IAS, while no substantial change was observed in CMP 382 (Fig. 5A). It's worth noting that the LA pathway and AA pathway are closely interrelated. The metabolism of linoleic acid involves a series of enzymatic 383 384 reactions that ultimately lead to the production of arachidonic acid (AA) and its 385 derivatives, including prostaglandins and leukotrienes, which play pivotal roles in inflammation, cardiovascular function, and other physiological processes. 386 387 Recent studies have indicated that the linoleic acid pathway may play a role in the development of coronary heart disease [39]. Specifically, research 388 389 suggests that mutations in the gene responsible for coding delta-6 desaturase 390 (D6D), the enzyme responsible for converting linoleic acid to arachidonic acid, could be associated with an increased risk of coronary heart disease<sup>39</sup>. 391 392 Furthermore, LA metabolism may also interact with other molecular pathways 393 involved in cardiac development, such as the Wnt signaling pathway, which has been implicated in CHD pathogenesis<sup>40-42</sup>. Although the exact 394 395 mechanisms by which dysregulation of the LA metabolism pathway contributes 396 to CHD are not yet fully understood, the linoleic acid metabolism pathway has 397 emerged as a potential contributor to the pathogenesis of congenital heart disease. These findings highlight the importance of further research into this 398 399 metabolic pathway and its potential implications in CHD development and 400 progression.

401 Monoradylglycerols (MG) are a type of lipid molecule characterized by a 402 glycerol backbone with a single fatty acid molecule attached to it. These lipids 403 are commonly found in various foods, particularly in processed foods that

404 contain added fats and oils. Currently, there is no direct evidence to suggest 405 that MG are directly linked to the development of CHD. However, studies have 406 demonstrated that a diet high in saturated fats, often found in processed foods 407 containing MG, may indeed increase the risk of developing CHD. High-fat diets in expectant mothers have been shown to enhance the expression of placental 408 mRNA associated with the arachidonic acid (AA) metabolism pathway<sup>43</sup>. This 409 can lead to elevated fetal arachidonic acid levels due to maternal arachidonic 410 acid transfer, resulting in an upregulation of fetal VEGF expression<sup>44</sup>. 411 412 Consequently, an overexpression of VEGF in the myocardium may impede the 413 process of epithelial-mesenchymal transformation, which is crucial for 414 endocardial cushion formation. Such impairment of endocardial cushion formation can trigger defects in septation and outflow tract development<sup>45</sup>. In 415 416 this context, Smedts et al. reported that a high maternal intake of saturated fat is associated with a higher likelihood of developing outflow tract defects<sup>46</sup>. 417 418 Furthermore, these researchers found that infants born to mothers with abnormal lipid profiles have twice the risk of CHD<sup>47</sup>. While MG themselves 419 420 may not be directly linked to CHD, their presence in processed foods that are 421 high in saturated fats may contribute to an increased risk of developing CHD over time. In conclusion, while MG are not directly implicated in CHD 422 423 development, their association with processed foods high in saturated fats underscores the importance of dietary considerations in reducing the risk of 424 425 CHD. Adopting a balanced and healthy diet may help mitigate potential risks associated with the consumption of saturated fats and processed foods. 426

The QHQ pathway is a vital metabolic pathway responsible for maintaining cellular homeostasis and safeguarding cells against oxidative stress. Its

429 primary function involves regulating the redox balance in cells by converting 430 guinones to hydroguinones, which helps control oxidative stress. Oxidative 431 stress arises when there is an imbalance between reactive oxygen species 432 (ROS) production and the cellular antioxidant defense system. Excessive ROS 433 production can lead to oxidative damage of cellular components, such as DNA, 434 proteins, and lipids, ultimately resulting in cellular dysfunction and cell death. 435 This oxidative stress condition has been implicated in the pathogenesis of various diseases, including CHD. Prior studies have highlighted the 436 437 involvement of oxidative stress in the development of heart malformations. impaired cardiac function, and other complications associated with CHD<sup>48</sup>. 438 439 Both cyanotic and acyanotic congenital heart diseases have been shown to induce a pro-oxidant state in the human body, leading to increased levels of 440 441 total antioxidants, oxidants, and the oxidative stress index in affected children<sup>49,50</sup>. In our study, we observed that the QHQ pathway showed 442 443 significant differences only in CMP patients (Fig. 5B). However, further 444 research is warranted to fully comprehend the underlying mechanisms by which oxidative stress contributes to CHD development. Additionally, 445 446 identifying potential markers for the early diagnosis of this condition could be 447 crucial in advancing CHD management and treatment strategies. In summary, the QHQ pathway's involvement in cellular redox regulation and oxidative 448 449 stress highlights its potential significance in CHD pathogenesis. Understanding 450 its role could provide valuable insights into the development and progression 451 of CHD and pave the way for novel therapeutic interventions and diagnostic 452 approaches.

453 Furthermore, our study involved targeted metabolomics to profile amino acids, 454 acylcarnitines, and lipids, given their central role in the pathogenesis of heart 455 disease. Carnitine and acylcarnitines play critical roles in energy metabolism, 456 especially in the transport of long-chain fatty acids into the mitochondria for energy production. Infants with CHD are particularly susceptible to energy 457 imbalances, and although most of them have normal weight at birth, they often 458 experience nutritional and growth problems in early infancy<sup>51</sup>. This has spurred 459 growing interest in investigating the potential of carnitine and acylcarnitine for 460 461 the diagnosis and management of CHD. Several studies have reported decreased levels of carnitine and acylcarnitines in patients with CHDs, 462 particularly those with ventricular overload or pulmonary hypertension<sup>52,53</sup>. 463 These decreases may indicate impaired cardiac metabolism and energy 464 465 production, which can contribute to the development of cardiomyopathy and 466 other complications. Beyond carnitine and acylcarnitines, Bahado-Singh et al. 467 conducted a study examining phosphatidylcholine (PC) levels in CHD patients. 468 PC is a major component of cell membranes and is vital for cell structure and function. In the context of CHD, disturbances in tissue remodeling may impact 469 470 the rate of cell membrane synthesis and destruction, leading to abnormal 471 choline and PC metabolism. Their study revealed significant abnormalities in 472 phosphatidylcholine (PC) and lipid levels in the serum of pregnant women 473 carrying CHD fetuses during the first trimester. Additionally, disturbances in carnitine levels and lipid synthesis were identified, potentially linked to 474 single-carbon metabolism through choline<sup>54</sup>. Consistent with these studies, our 475 476 research unveiled statistically significant alterations in acylcarnitine and PC 477 levels in DBS samples of CHD patients compared to those of healthy children.

Specifically, we identified C12-carnitine, C14:1 carnitine, and PC(d16:1-22:3)
as potential diagnostic markers for CHD. These findings provide valuable
insights into the metabolic changes associated with CHD and may offer
promising avenues for improved diagnosis and management of this condition.

482 Limitations

While our study shows promising potential for metabolomics in CHD newborn 483 484 screening, it is essential to acknowledge several limitations that may influence the interpretation of our findings. One of the primary limitations is the small 485 486 sample size used in our study, which may limit the representativeness of our 487 results to a broader population. To enhance the reliability and generalizability 488 of our findings, future research should strive to include larger cohorts, allowing 489 for more robust statistical analysis and validation of the identified biomarkers. 490 Furthermore, it is worth noting that our study was conducted at a specific 491 location, California, USA, which could introduce potential biases related to 492 sample collection, processing, and data analysis. To overcome this limitation 493 and increase the external validity of our findings, conducting multicenter studies in different regions with diverse populations would be highly beneficial. 494 Another important limitation of our study is the lack of consideration for 495 potential confounding factors that may influence the identified biomarkers. 496 497 Factors such as prenatal exposures, maternal health, and perinatal variables 498 could have an impact on the metabolic signature of CHD. Future research 499 should take these confounders into account to gain a more comprehensive understanding of their influence on metabolomic profiles in CHD. In conclusion, 500 while our study provides valuable insights into the potential of metabolomics in 501

502 CHD screening, it is crucial to recognize and address these limitations in future 503 investigations. By doing so, we can further enhance the reliability and 504 applicability of metabolomics in early CHD detection and potentially improve 505 patient outcomes.

#### 506 **Conclusion**

507 Newborn screening using tandem mass spectrometry has been widely 508 adopted as a public health strategy in developed countries to detect inborn errors of metabolism. However, its sensitivity for detecting critical congenital 509 510 heart disease (CHD) remains relatively low, necessitating the urgent 511 exploration of CHD-related biomarkers. In our study, we have made significant 512 progress in this area. Our research has demonstrated the excellent stability of 513 amino acids and acyl carnitines in dried blood spots (DBS) even after 514 extended storage of up to 15 years. Leveraging this stability, we identified 515 dysregulated metabolic pathways in CHD patients, including alterations in lipid 516 metabolism, energy metabolism, and oxidative stress pathways. Furthermore, through targeted metabolomics, we successfully uncovered potential 517 diagnostic biomarkers, such as acylcarnitines and phosphatidylcholine (PC). 518 519 These identified biomarker metabolites associated with CHD diagnosis and subtyping hold promising potential as a metabolic signature for CHD newborn 520 521 screening. This exciting finding opens the door to potential clinical applications 522 of metabolomics in facilitating early CHD detection and assessment, utilizing dry blood spot samples. Moreover, by further investigating the biomarker 523 metabolites and their underlying enriched pathways, we may gain deeper 524 insights into the mechanisms underlying CHD pathophysiology. This can lead 525

to a better understanding of CHD development, which has implications for future research, treatments, and improved patient outcomes. In conclusion, our study highlights the significant progress made in the application of metabolomics for CHD newborn screening and the identification of potential biomarkers. By unraveling the metabolic changes associated with CHD, we can move closer to developing effective screening methods and enhancing our understanding of CHD's pathogenesis.

## 533 Tables

Characters	Control -	CHD			P-valu
Characters	Control	TOF	IAS	СМР	e
Total	5	4	5	6	
Diagnosis					< 0.001
Normal	5 (100)	O (O)	0 (0)	0 (0)	
Tetralogy of Fallot	0 (0)	4 (100)	0 (0)	0 (0)	
Brugada syndrome	0 (0)	0 (0)	2 (40)	0 (0)	
Long QT syndrome	0 (0)	O (O)	3 (60)	0 (0)	
Dilated cardiomyopathy	0 (0)	0 (0)	0 (0)	3 (50)	
Hypertrophic cardiomyopathy	O (O)	0 (0)	0 (0)	3 (50)	

**Table 1.** The demographics of CDPH DBS Samples.

Age					
mean (SD)	0 (0)	0 (0)	0 (0)	0 (0)	
Gender					0.929
Female	2 (40)	2 (50)	3 (60)	2 (33.3)	
Male	3 (60)	2 (50)	2 (40)	4 (66.7)	
Race					0.168
Asian	O (O)	1 (25)	0 (0)	1 (16.7)	
Black	1 (20)	0 (0)	0 (0)	0 (0)	
Hispanic	0 (0)	1 (25)	4 (80)	3 (50)	
White	4 (80)	2 (50)	1 (20)	2 (33.3)	
CDPH DBS NBS records					
Thyroid stimulating	6 7 (4 7)	E C (E A)	5.5 (3.9)	4.4 (1.7)	0 0 1 7
hormone, mean (SD)	6.7 (4.7)	5.6 (5.4)	5.5 (5.9)	4.4 (1.7)	0.817
C8-Carnitine, mean (SD)	0.1 (0)	0 (0)	0.1 (0)	0.1 (0)	0.011
Galactose-1-phosphate	247.2	219.1	260 F	308.5	
uridyl transferase, median	(217,267.	(170.6,274.	269.5	(304.3,314.	0.166
(IQR)	5)	6)	(260.4,271)	1)	
	105.9	102.7	114.3	00 (20 0)	0.74
Valine, mean (SD)	(19.3)	(60.9)	(40.7)	90 (20.9)	0.74
C18:1-Carnitine, mean (SD)	1.2 (0.3)	0.9 (0.5)	1 (0.3)	1.2 (0.3)	0.513
C160H-Carnitine	0 (0)	0 (0)	0 (0)	0 (0)	0.164

# /C16-Carnitine Ratio, mean

(SD)

C16:1-Carnitine, mean (SD)	0.3 (0)	0.1 (0.1)	0.2 (0.1)	0.3 (0.1)	0.02
17-Hydroxyprogesterone	13.3 (8.9)	18.3 (8.8)	22.3 (18.6)	10.9 (3.4)	0.378
(17-OHP), mean (SD)					
C3-Carnitine / C2-Carnitine	0.1 (0)	0.1 (0)	0.1 (0)	0.1 (0)	0.291
Ratio, mean (SD)	0.1 (0)	0.1 (0)	0.1 (0)	0.1 (0)	0.291
C14-Carnitine, mean (SD)	0.3 (0)	0.2 (0.1)	0.2 (0)	0.2 (0.1)	0.005
Methionine, mean (SD)	28 (6.1)	25.5 (12.4)	20.2 (4.7)	26 (5.5)	0.397
	220 (00 8)	369.8	207 2 (74)	207 2 (100)	0.270
Alanine, mean (SD)	230 (96.8)	(180.5)	307.2 (74)	307.3 (109)	0.379
Immunoreactive	17.7 (7.7)	15.9 (2.5)	30.8 (16.1)	18.6 (8.3)	0.131
trypsinogen, mean (SD)	<b>1</b> 7.7 (7.7)	13.3 (2.3)	50.0 (10.1)	10.0 (0.3)	0.151
Ornithine/Citrulline Ratio,	5.7	6.5	4.8	4.6	0.385
median (IQR)	(4.7,7.5)	(5.5,8.8)	(4.8,8.4)	(4.3,4.9)	0.565
Arginine/Ornithine Ratio,	0.1 (0)	0.1 (0.1)	0.1 (0.1)	0.1 (0.1)	0.919
mean (SD)	0.1 (0)	0.1 (0.1)	0.1 (0.1)	0.1 (0.1)	0.919
Leucine/Isoleucine, median	99.1	86.7	95.4	88.9	
	(93.4,113.	(61.2,133.5	(62.8,106.5	(85.2,100.7	0.838
(IQR)	2)	)	)	)	
C12-Carnitine, mean (SD)	0.2 (0.1)	0 (0)	0.1 (0.1)	0.1 (0)	0.016
C18:2-Carnitine, median	0.1	0.3	0.1	0.2	0.278

(IQR)	(0.1,0.2)	(0.2,0.6)	(0.1,0.3)	(0.1,0.2)	
Glycine, mean (SD)	525.6	448 (213.7)	471.8	553.5	0.521
Giyelle, mean (50)	(89.3)	440 (213.7)	(105.1)	(68.6)	0.521
C6-Carnitine, mean (SD)	0.1 (0)	0 (0)	0 (0)	0.1 (0)	0.097
C5OH-Carnitine, median	0.2	0.2	0.2	0.2	0.579
(IQR)	(0.1,0.2)	(0.2,0.2)	(0.2,0.3)	(0.2,0.2)	0.375
Succinylacetone, mean (SD)	0.5 (0.3)	0.2 (0.1)	0.6 (0.4)	0.4 (0.3)	0.33
C12:1-Carnitine, mean (SD)	0.1 (0.1)	0 (0)	0.1 (0.1)	0.1 (0)	0.018
Arginine	8.6 (2.6)	8.8 (7.9)	9.2 (3.1)	7.5 (6.6)	0.96
C18:10H-Carnitine, mean	0 (0)	0 (0)	0.(0)	0 (0)	0 1 9 4
(SD)	0 (0)	0 (0)	0 (0)	0 (0)	0.184
C3DC-Carnitine					
/C10-Carnitine Ratio, mean	1.3 (0.4)	2.7 (0.9)	1.7 (0.6)	2.1 (1.2)	0.157
(SD)					
FC, mean (SD)	19.6 (5.9)	28 (11.2)	25.3 (12.5)	19 (4.6)	0.352
Leucine/Alanine Ratio, mean		0.2 (0.1)		0.2 (0.1)	0.425
(SD)	0.5 (0.2)	0.3 (0.1)	0.3 (0.2)	0.3 (0.1)	0.135
Citrulline/Arginine Ratio,	2.1.(0.0)	2 0 (2 2)	1 7 /1)	4 1 /2 4)	0.221
mean (SD)	2.1 (0.9)	2.8 (2.2)	1.7 (1)	4.1 (3.4)	0.331
C14:2-Carnitine, mean (SD)	0 (0)	0 (0)	0 (0)	0 (0)	0.1
C4 Compiliant modifier (IOD)	0.3	0.2	0.2	0.2	0.001
C4-Carnitine, median (IQR)	(0.2,0.3)	(0.1,0.3)	(0.2,0.3)	(0.2,0.2)	0.691

C8:1-Carnitine, mean (SD)	0.1 (0)	0.1 (0)	0.1 (0)	0.1 (0)	0.216
Phenylalanine/Tyrosine	0.6	0.9 (0.9,1)	0.7	0.6	0.036
Ratio, median (IQR)	(0.6,0.7)	0.9 (0.9,1)	(0.7,0.8)	(0.6,0.7)	0.030
C2-Carnitine, mean (SD)	23.7 (9.8)	26.6 (11.4)	20 (4.5)	23.6 (7.2)	0.701
Biotinidase, mean (SD)	43.4 (10.3)	41.7 (5.6)	51.4 (13.8)	42.7 (7.5)	0.417
C5DC-Carnitine, mean (SD)	0.2 (0.1)	0.1 (0)	0.2 (0.1)	0.2 (0.1)	0.104
C18OH-Carnitine, median (IQR)	0 (0,0)	0 (0,0)	0 (0,0)	0 (0,0)	0.086
C3-Carnitine, mean (SD)	1.6 (0.4)	2.1 (0.9)	1.6 (0.5)	2.2 (0.6)	0.318
C18-Carnitine, mean (SD)	0.8 (0.2)	0.8 (0.2)	0.7 (0.1)	0.8 (0.2)	0.454
C14:1-Carnitine /					
C12:1-Carnitine Ratio, mean	1.3 (0.1)	1.7 (0.9)	1.2 (0.4)	1.6 (0.4)	0.51
(SD)					
C10-Carnitine, mean (SD)	0.1 (0)	O (O)	0.1 (0)	0.1 (0)	0.005
C5:1-Carnitine, median (IQR)	0 (0,0)	0 (0,0)	0 (0,0)	0 (0,0)	0.51
5-Oxoproline, mean (SD)	21.8 (5)	32 (7.4)	26.8 (6.6)	25.2 (8.2)	0.221
C10:1-Carnitine, mean (SD)	0.1 (0)	O (O)	0.1 (0)	O (O)	0.238
C5-Carnitine, mean (SD)	0.1 (0)	0.1 (0.1)	0.1 (0)	0.1 (0)	0.978
Phenylalanine, mean (SD)	63.9 (8.2)	69.8 (33.3)	55.4 (19.7)	66.6 (15.8)	0.719
Proline, mean (SD)	203.4	159.8	180.8	179.2	0.593
	(38.2)	(73.4)	(43.6)	(33.7)	0,000

C16OH-Carnitine, mean (SD)	0 (0)	O (O)	O (O)	O (O)	0.032
	103.6			102.7	0.45
Tyrosine, mean (SD)	(17.7)	72.6 (35.5)	68.7 (30.1)	(32.7)	0.15
	98.6	103.8	102 (52.1)	70.0 (20)	0.000
Ornithine, mean (SD)	(44.5)	(92.5)	102 (53.1)	79.8 (28)	0.882
FC / (C16-Carnitine +					
C18:1-Carnitine) Ratio,	4.3 (3.9,5)	8.1 (7.3,9)	6.7 (5,7.1)	4.5 (3.7,5)	0.037
median (IQR)					
C16-Carnitine, mean (SD)	3.4 (1)	2.5 (0.9)	2.3 (0.3)	3.1 (0.8)	0.166
C14OH-Carnitine, mean (SD)	0 (0)	0 (0)	0 (0)	0 (0)	0.012
C3DC-Carnitine, mean (SD)	0.1 (0)	0.1 (0)	0.1 (0)	0.1 (0)	0.02
C14:1-Carnitine, mean (SD)	0.2 (0.1)	0 (0)	0.1 (0)	0.1 (0)	0.004
C5-Carnitine /C3-Carnitine	0.1.(0)	0.1.(0)	0.1.(0)	0.1.(0)	0.070
Ratio, mean (SD)	0.1 (0)	0.1 (0)	0.1 (0)	0.1 (0)	0.279
C8-Carnitine /C10-Carnitine			4 (2.2)		0.470
Ratio, mean (SD)	0.7 (0.1)	1 (0.5)	1 (0.3)	0.8 (0.1)	0.472
Citrulline, mean (SD)	16.6 (3.6)	11.8 (3.9)	14 (6)	17 (3.2)	0.242
Valine / Phenylalanine Ratio,	1 7 (0 2)	1 5 /0 4 \	10/04)	1 / (0 2)	0 1 4 7
mean (SD)	1.7 (0.3)	1.5 (0.4)	1.9 (0.4)	1.4 (0.3)	0.147

535 Values are mean ± SD or numbers (percentages). SD: Standard deviation; IQR:

536 Interquartile Range. CHD: Congenital heart disease. TOF: Tetralogy of Fallot. IAS:

537 Inherited arrhythmias syndromes. CMP: Cardiomyopathies.

538

# 539 **Table 2.** Discernibility ability to CHD subtypes by global hydrophilic and

540 hydrophobic metabolomics with orthogonal partial least squares discriminant

	Hydrophilic		Hydro	ophobic
	AUC	P-value	AUC	P-value
HC vs Other(s)	1.00	0.001	1.00	0.001
CMP vs Other(s)	0.881	0.008	0.607	0.458
IAS vs Other(s)	0.533	0.827	0.987	0.001
TOF vs Other(s)	0.969	0.005	0.906	0.014

541 analysis (OPLS-DA).

542 HC: Health Control. TOF: Tetralogy of Fallot. IAS: Inherited arrhythmias syndromes. CMP:

543 Cardiomyopathies.

# 544 **Figures**

Figure 1. Study workflow diagram to apply metabolomic analytics to the neonate DBS samples and to discover CHD biomarkers. Abbreviations: CHD-Congenital heart disease, TOF- Tetralogy of Fallot, IAS- Inherited arrhythmias syndromes, CMP- Cardiomyopathies.

Figure 2. Statistical distribution of DBS Samples storage times in California
 Department of Public Health (CDPH) Lab.

Figure 3. Impact of the time storage of metabolites. A) scatter plots showing the positive correlations of metabolic profiling between this study (X-axis) and the CDPH DBS records (Y-axis). B) Statistical distribution of the correlation coefficient.

**Figure 4.** Orthogonal partial least squares discriminant analysis (OPLS-DA) using the global hydrophilic and hydrophobic metabolic profiling results of health control (HC), CHD-Tetralogy of Fallot (TOF), CHD-inherited arrhythmia syndromes (IAS) and CHD-cardiomyopathies (CMP). A) clustering results of hydrophilic metabolic profiling B) clustering results of hydrophobic metabolic profiling.

Figure 5. Significant Metabolic pathways altered in different CHD subtypes.
Pathway enrichment analysis on the A) global hydrophilic and B) hydrophobic
metabolic profiling. All significant changed components (P value <0.05,</li>
Student's t-test) in CHD-Tetralogy of Fallot (TOF), CHD-inherited arrhythmia
syndromes (IAS) and CHD-cardiomyopathies (CMP) are mapping to KEGG
metabolic pathways and Lipid Map database, respectively. \*: P value <0.05, \*\*:</li>
P value <0.01, \*\*\*: P value <0.001.</li>

**Figure 6.** The application of targeted metabolomics to discover CHD diagnosis and subtyping biomarker metabolites using DBS samples. A) Volcano plots for screening significant changed metabolites associated with CHD, the metabolites with P value < 0.05 and fold change >1.5 are marked as red dots and the metabolites with P value < 0.05 and fold change < 0.67 are marked as blue dots. B) violin plots for three biomarker metabolites for CHD diagnosis. \*: Student's P value <0.05, \*\*: P value <0.01, \*\*\*: P value <0.001. C) the</li>
smoothed receiver operating characteristic curve (AUC ROC) of logistic model
based on three biomarkers. 95% confidence intervals are shown in grey lines.
D) the importance score of the 12 metabolites associated with CHD subtyping
which have an 80% cumulative importance in total. E) PLS-DA cluster results
using 12 metabolites for CHD subtyping.

**Figure 7.** CHD Subtyping modeling with targeted metabolomic profiling analysis of newborn DBS samples. A) Confusion matrix. B) AUC curves to demonstrate the performance to diagnose CHD subtypes.

#### 583 Acknowledgements

The biospecimens and/or data (Request ID: 1893) used in this study were obtained from the California Biobank Program (CBP) in accordance with Section 6555(a), 17 CCR. The California Department of Public Health is not responsible for the results or conclusions drawn by the authors of this publication.

#### 589 Author contributions

- 590 Experimental design: S.R. Ceresnac, X.B.Ling
- 591 Mass spectrometric assay development: X.B.Ling, Y. Zhang, K.J. Su, J.
- 592 Schilling, R.Y. Luo
- 593 Sample procurement and data entry: S.R. Ceresnac, X.B.Ling, Y. Zhang
- 594 Data analysis: Q. Tang, B. Jin, C.J. Chou, Z. Han, L. Tian,

- 595 Clinical Interpretation: S.R. Ceresnac, B.J. Floyd, K.G. Sylvester, H. Chubb,
- 596 H.J. Cohen, Doff. McElhinney
- 597 Manuscript preparation: S.R. Ceresnac, X.B.Ling, Y. Zhang, J.C. Whitin, K.G.
- 598 Sylvester, H. Chubb, , H.J. Cohen, D.B. McElhinney
- 599 **Competing interests**
- K.J. Su, Q. Tang, J. Schilling, B. Jin are staff members of mProbe Inc. The rest
- of the authors declare no conflict of interest. The funders had no role in the
- design of the study; in the collection, analyses, or interpretation of data; in the
- writing of the manuscript; or in the decision to publish the results.

# 604 **References**

605 1. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-1900. doi: 10.1016/s0735-1097(02)01886-7 606 607 2. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease 608 609 worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241-2247. doi: 10.1016/j.jacc.2011.08.025 610 3. Baird PA, Sadovnick AD, Yee IM. Maternal age and birth defects: a population 611 study. Lancet. 1991;337:527-530. doi: 10.1016/0140-6736(91)91306-f 612 613 4. Wang Z, Li L, Lei XY, Xue J, Mi HY. [Effect of advanced maternal age on birth 614 defects and postnatal complications of neonates]. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18:1084-1089. 615 5. Khairy P, Ionescu-Ittu R, Mackie AS, Abrahamowicz M, Pilote L, Marelli AJ. 616 617 Changing mortality in congenital heart disease. J Am Coll Cardiol. 618 2010;56:1149-1157. doi: 10.1016/j.jacc.2010.03.085 619 6. Thangaratinam S, Brown K, Zamora J, Khan KS, Ewer AK. Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a 620 621 systematic review and meta-analysis. *Lancet*. 2012;379:2459-2464. doi: 622 10.1016/S0140-6736(12)60107-X 623 7. Diller CL, Kelleman MS, Kupke KG, Quary SC, Kochilas LK, Oster ME. A Modified Algorithm for Critical Congenital Heart Disease Screening Using Pulse 624 625 Oximetry. Pediatrics. 2018;141. doi: 10.1542/peds.2017-4065

626	8.	Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R,
627		Gidding SS, Beekman RH, 3rd, Grosse SD, American Heart Association
628		Congenital Heart Defects Committee of the Council on Cardiovascular Disease in
629		the Young CoCN, et al. Role of pulse oximetry in examining newborns for
630		congenital heart disease: a scientific statement from the American Heart
631		Association and American Academy of Pediatrics. <i>Circulation</i> . 2009;120:447-458.
632		doi: 10.1161/CIRCULATIONAHA.109.192576
633	9.	Dalal A, Czosek RJ, Kovach J, von Alvensleben JC, Valdes S, Etheridge SP,
634		Ackerman MJ, Auld D, Huckaby J, McCracken C, et al. Clinical Presentation of
635		Pediatric Patients at Risk for Sudden Cardiac Arrest. J Pediatr. 2016;177:191-196.
636		doi: 10.1016/j.jpeds.2016.06.088
637	10	Kruska M, El-Battrawy I, Behnes M, Borggrefe M, Akin I. Biomarkers in
638		Cardiomyopathies and Prediction of Sudden Cardiac Death. Curr Pharm
639		Biotechnol. 2017;18:472-481. doi: 10.2174/1389201018666170623125842
640	11	Chatterjee D, Fatah M, Akdis D, Spears DA, Koopmann TT, Mittal K, Rafiq MA,
641		Cattanach BM, Zhao Q, Healey JS, et al. An autoantibody identifies
642		arrhythmogenic right ventricular cardiomyopathy and participates in its
643		pathogenesis. Eur Heart J. 2018;39:3932-3944. doi: 10.1093/eurheartj/ehy567
644	12	Coats CJ, Heywood WE, Mills K, Elliott PM. Current applications of biomarkers
645		in cardiomyopathies. Expert Rev Cardiovasc Ther. 2015;13:825-837. doi:
646		10.1586/14779072.2015.1053873
647	13	Fastner C, Behnes M, Sartorius B, Wenke A, Lang S, Yucel G, Sattler K, Rusnak
648		J, Saleh A, Barth C, et al. Interventional Left Atrial Appendage Closure Affects
649		the Metabolism of Acylcarnitines. Int J Mol Sci. 2018;19. doi:
650		10.3390/ijms19020500
651	14	Altit G, Bhombal S, Tacy TA, Chock VY. End-Organ Saturation Differences in
652		Early Neonatal Transition for Left- versus Right-Sided Congenital Heart Disease.
653		Neonatology. 2018;114:53-61. doi: 10.1159/000487472
654	15	Reddy S, Zhao M, Hu DQ, Fajardo G, Katznelson E, Punn R, Spin JM, Chan FP,
655		Bernstein D. Physiologic and molecular characterization of a murine model of
656		right ventricular volume overload. Am J Physiol Heart Circ Physiol.
657		2013;304:H1314-1327. doi: 10.1152/ajpheart.00776.2012
658	16	Bove T, Vandekerckhove K, Bouchez S, Wouters P, Somers P, Van Nooten G.
659		Role of myocardial hypertrophy on acute and chronic right ventricular
660		performance in relation to chronic volume overload in a porcine model: relevance
661		for the surgical management of tetralogy of Fallot. J Thorac Cardiovasc Surg.
662		2014;147:1956-1965. doi: 10.1016/j.jtcvs.2013.10.026
663	17	Del Duca D, Wong G, Trieu P, Rodaros D, Kouremenos A, Tadevosyan A,
664		Vaniotis G, Villeneuve LR, Tchervenkov CI, Nattel S, et al. Association of
665		neonatal hypoxia with lasting changes in left ventricular gene expression: an
666		animal model. J Thorac Cardiovasc Surg. 2009;138:538-546, 546 e531. doi:
667		10.1016/j.jtcvs.2009.04.042

668	18. Liao P, Soong TW. CaV1.2 channelopathies: from arrhythmias to autism, bipolar
669	disorder, and immunodeficiency. <i>Pflugers Arch.</i> 2010;460:353-359. doi:
670	10.1007/s00424-009-0753-0
671	19. la Marca G, Carling RS, Moat SJ, Yahyaoui R, Ranieri E, Bonham JR, Schielen P.
672	Current State and Innovations in Newborn Screening: Continuing to Do Good and
673	Avoid Harm. Int J Neonatal Screen. 2023;9. doi: 10.3390/ijns9010015
674	20. Sinclair TJ, Ye C, Chen Y, Zhang D, Li T, Ling XB, Cohen HJ, Shaw GM,
675	Stevenson DK, Chace D, et al. Progressive Metabolic Dysfunction and Nutritional
676	Variability Precedes Necrotizing Enterocolitis. <i>Nutrients</i> . 2020;12. doi:
677	10.3390/nu12051275
678	21. Zhu L, Huang Q, Li X, Jin B, Ding Y, Chou CJ, Su KJ, Zhang Y, Chen X, Hwa
679	KY, et al. Serological Phenotyping Analysis Uncovers a Unique Metabolomic
680	Pattern Associated With Early Onset of Type 2 Diabetes Mellitus. Front Mol
681	<i>Biosci</i> . 2022;9:841209. doi: 10.3389/fmolb.2022.841209
682	22. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG:
683	integrating viruses and cellular organisms. Nucleic Acids Res.
684	2021;49:D545-D551. doi: 10.1093/nar/gkaa970
685	23. Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, Spener
686	F, van Meer G, Wakelam MJ, Dennis EA. Update of the LIPID MAPS
687	comprehensive classification system for lipids. J Lipid Res. 2009;50 Suppl:S9-14.
688	doi: 10.1194/jlr.R800095-JLR200
689	24. Bradshaw CJA, Herrando-Perez S. Logistic-growth models measuring density
690	feedback are sensitive to population declines, but not fluctuating carrying capacity.
691	Ecol Evol. 2023;13:e10010. doi: 10.1002/ece3.10010
692	25.Peng Y, Zhao S, Zeng Z, Hu X, Yin Z. LGBMDF: A cascade forest framework
693	with LightGBM for predicting drug-target interactions. Front Microbiol.
694	2022;13:1092467. doi: 10.3389/fmicb.2022.1092467
695	26. Ke G, Meng Q, Finley T, Wang T, Chen W, Ma W, Ye Q, Liu T-Y. LightGBM: a
696	highly efficient gradient boosting decision tree. In: Proceedings of the 31st
697	International Conference on Neural Information Processing Systems. Long Beach,
698	California, USA: Curran Associates Inc.; 2017:3149–3157.
699	27. Hakuno D, Hamba Y, Toya T, Adachi T. Plasma amino acid profiling identifies
700	specific amino acid associations with cardiovascular function in patients with
701	systolic heart failure. PLoS One. 2015;10:e0117325. doi:
702	10.1371/journal.pone.0117325
703	28. Fukushima A, Zhang L, Huqi A, Lam VH, Rawat S, Altamimi T, Wagg CS,
704	Dhaliwal KK, Hornberger LK, Kantor PF, et al. Acetylation contributes to
705	hypertrophy-caused maturational delay of cardiac energy metabolism. JCI Insight.
706	2018;3. doi: 10.1172/jci.insight.99239
707	29. Wang B, Wu L, Chen J, Dong L, Chen C, Wen Z, Hu J, Fleming I, Wang DW.
708	Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic
709	targets. Signal Transduct Target Ther. 2021;6:94. doi:
710	10.1038/s41392-020-00443-w

711	30. Yang LG, Song ZX, Yin H, Wang YY, Shu GF, Lu HX, Wang SK, Sun GJ. Low
712	n-6/n-3 PUFA Ratio Improves Lipid Metabolism, Inflammation, Oxidative Stress
713	and Endothelial Function in Rats Using Plant Oils as n-3 Fatty Acid Source.
714	<i>Lipids</i> . 2016;51:49-59. doi: 10.1007/s11745-015-4091-z
715	31. Kanoh M, Inai K, Shinohara T, Tomimatsu H, Nakanishi T. Clinical implications
716	of eicosapentaenoic acid/arachidonic acid ratio (EPA/AA) in adult patients with
717	congenital heart disease. Heart Vessels. 2017;32:1513-1522. doi:
718	10.1007/s00380-017-1015-2
719	32. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L,
720	Rabinovitch M, Zamanian RT, et al. Blocking macrophage leukotriene b4 prevents
721	endothelial injury and reverses pulmonary hypertension. Sci Transl Med.
722	2013;5:200ra117. doi: 10.1126/scitranslmed.3006674
723	33. Vrigkou E, Tsantes AE, Kopterides P, Orfanos SE, Armaganidis A, Maratou E,
724	Rapti E, Pappas A, Tsantes AG, Tsangaris I. Coagulation Profiles of Pulmonary
725	Arterial Hypertension Patients, Assessed by Non-Conventional Hemostatic Tests
726	and Markers of Platelet Activation and Endothelial Dysfunction. <i>Diagnostics</i>
727	(Basel). 2020;10. doi: 10.3390/diagnostics10100758
728	34. Gu H, Fang YJ, Liu DD, Chen P, Mei YA. cAMP/PKA Pathways and S56
729	Phosphorylation Are Involved in AA/PGE2-Induced Increases in rNaV1.4
730	Current. PLoS One. 2015;10:e0140715. doi: 10.1371/journal.pone.0140715
731	35. Lai J, Chen C. The Role of Epoxyeicosatrienoic Acids in Cardiac Remodeling.
732	Front Physiol. 2021;12:642470. doi: 10.3389/fphys.2021.642470
733	36. Evangelista EA, Aliwarga T, Sotoodehnia N, Jensen PN, McKnight B, Lemaitre
734	RN, Totah RA, Gharib SA. CYP2J2 Modulates Diverse Transcriptional Programs
735	in Adult Human Cardiomyocytes. Sci Rep. 2020;10:5329. doi:
736	10.1038/s41598-020-62174-w
737	37. Li N, Liu JY, Qiu H, Harris TR, Sirish P, Hammock BD, Chiamvimonvat N. Use
738	of metabolomic profiling in the study of arachidonic acid metabolism in
739	cardiovascular disease. Congest Heart Fail. 2011;17:42-46. doi:
740	10.1111/j.1751-7133.2010.00209.x
741	38. Levick SP, Loch DC, Taylor SM, Janicki JS. Arachidonic acid metabolism as a
742	potential mediator of cardiac fibrosis associated with inflammation. J Immunol.
743	2007;178:641-646. doi: 10.4049/jimmunol.178.2.641
744	39. Aslibekyan S, Jensen MK, Campos H, Linkletter CD, Loucks EB, Ordovas JM,
745	Deka R, Rimm EB, Baylin A. Fatty Acid desaturase gene variants, cardiovascular
746	risk factors, and myocardial infarction in the costa rica study. Front Genet.
747	2012;3:72. doi: 10.3389/fgene.2012.00072
748	40. Pahnke A, Conant G, Huyer LD, Zhao Y, Feric N, Radisic M. The role of Wnt
749	regulation in heart development, cardiac repair and disease: A tissue engineering
750	perspective. Biochem Biophys Res Commun. 2016;473:698-703. doi:
751	10.1016/j.bbrc.2015.11.060
752	41. Wang J, Liang Y, Jian L, Zhang J, Liang S, Xiao S, Liu B, Wang H. Linoelaidic
753	acid enhances adipogenic differentiation in adipose tissue-derived stromal cells
754	through suppression of Wnt/beta-catenin signaling pathway in vitro.

755	Prostaglandins Leukot Essent Fatty Acids. 2016;110:1-7. doi:
756	10.1016/j.plefa.2016.04.004
757	42. Mohamed IA, El-Badri N, Zaher A. Wnt Signaling: The double-edged sword
758	diminishing the potential of stem cell therapy in congenital heart disease. Life Sci.
759	2019;239:116937. doi: 10.1016/j.lfs.2019.116937
760	43. Dekker Nitert M, Vaswani K, Hum M, Chan HW, Wood-Bradley R, Henry S,
761	Armitage JA, Mitchell MD, Rice GE. Maternal high-fat diet alters expression of
762	pathways of growth, blood supply and arachidonic acid in rat placenta. J Nutr Sci.
763	2013;2:e41. doi: 10.1017/jns.2013.36
764	44. Lee SH, Kim MH, Han HJ. Arachidonic acid potentiates hypoxia-induced VEGF
765	expression in mouse embryonic stem cells: involvement of Notch, Wnt, and
766	HIF-1alpha. Am J Physiol Cell Physiol. 2009;297:C207-216. doi:
767	10.1152/ajpcell.00579.2008
768	45. Lambrechts D, Carmeliet P. Genetics in zebrafish, mice, and humans to dissect
769	congenital heart disease: insights in the role of VEGF. Curr Top Dev Biol.
770	2004;62:189-224. doi: 10.1016/S0070-2153(04)62007-2
771	46. Smedts HP, Rakhshandehroo M, Verkleij-Hagoort AC, de Vries JH, Ottenkamp J,
772	Steegers EA, Steegers-Theunissen RP. Maternal intake of fat, riboflavin and
773	nicotinamide and the risk of having offspring with congenital heart defects. Eur J
774	Nutr. 2008;47:357-365. doi: 10.1007/s00394-008-0735-6
775	47. Smedts HP, van Uitert EM, Valkenburg O, Laven JS, Eijkemans MJ, Lindemans J,
776	Steegers EA, Steegers-Theunissen RP. A derangement of the maternal lipid profile
777	is associated with an elevated risk of congenital heart disease in the offspring. Nutr
778	Metab Cardiovasc Dis. 2012;22:477-485. doi: 10.1016/j.numecd.2010.07.016
779	48. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac
780	physiology and pathology. Circ Res. 2012;111:1091-1106. doi:
781	10.1161/CIRCRESAHA.111.255216
782	49. Manso PH, Carmona F, Dal-Pizzol F, Petronilho F, Cardoso F, Castro M, Carlotti
783	AP. Oxidative stress markers are not associated with outcomes after pediatric heart
784	surgery. Paediatr Anaesth. 2013;23:188-194. doi: 10.1111/pan.12040
785	50. Calza G, Lerzo F, Perfumo F, Borini I, Panizzon G, Moretti R, Grasso P, Virgone
786	A, Zannini L. Clinical evaluation of oxidative stress and myocardial reperfusion
787	injury in pediatric cardiac surgery. J Cardiovasc Surg (Torino). 2002;43:441-447.
788	51. Nydegger A, Bines JE. Energy metabolism in infants with congenital heart
789	disease. Nutrition. 2006;22:697-704. doi: 10.1016/j.nut.2006.03.010
790	52. Sun X, Sharma S, Fratz S, Kumar S, Rafikov R, Aggarwal S, Rafikova O, Lu Q,
791	Burns T, Dasarathy S, et al. Disruption of endothelial cell mitochondrial
792	bioenergetics in lambs with increased pulmonary blood flow. Antioxid Redox
793	Signal. 2013;18:1739-1752. doi: 10.1089/ars.2012.4806
794	53. Black SM, Field-Ridley A, Sharma S, Kumar S, Keller RL, Kameny R, Maltepe E,
795	Datar SA, Fineman JR. Altered Carnitine Homeostasis in Children With Increased
796	Pulmonary Blood Flow Due to Ventricular Septal Defects. Pediatr Crit Care Med.
797	2017;18:931-934. doi: 10.1097/PCC.000000000001275

- 54. Bahado-Singh RO, Ertl R, Mandal R, Bjorndahl TC, Syngelaki A, Han B, Dong E,
- Liu PB, Alpay-Savasan Z, Wishart DS, et al. Metabolomic prediction of fetal
- 800 congenital heart defect in the first trimester. Am J Obstet Gynecol. 2014;211:240
- e241-240 e214. doi: 10.1016/j.ajog.2014.03.056

802

# Figure 1.




Figure 2.




Figure 3.




Figure 3.




Figure 4.




Figure 5.




Figure 6.

